Net Cash Provided by (Used in) Operating Activities of Estrella Immunopharma, Inc. from 31 Mar 2021 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Estrella Immunopharma, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Mar 2021 to 31 Mar 2025.
  • Estrella Immunopharma, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2025 was $465,981, a 89% increase year-over-year.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was $16,068,306, a 1103% decline from 2023.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $1,336,121, a 28% decline from 2022.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $1,043,848, a 230% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Estrella Immunopharma, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $465,981 +$3,768,653 +89% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q3 2024 $2,217,460 -$1,942,268 -706% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2025 Q1
Q1 2024 $4,234,634 -$3,958,916 -1436% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q3 2023 $275,192 +$825,034 +75% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q1
Q1 2023 $275,718 -$118,574 -75% 01 Jan 2023 31 Mar 2023 10-Q 18 May 2023
Q3 2022 $1,100,226 01 Jul 2022 30 Sep 2022 10-Q 20 Nov 2023 2024 Q1
Q1 2022 $157,144 +$661,856 +81% 01 Jan 2022 31 Mar 2022 10-Q 18 May 2023
Q1 2021 $819,000 06 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1

Estrella Immunopharma, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $16,068,306 -$14,732,185 -1103% 01 Jul 2023 30 Jun 2024 10-KT 25 Mar 2025 2024 FY
2023 $1,336,121 -$292,273 -28% 01 Jul 2022 30 Jun 2023 10-K 27 Sep 2024 2024 FY
2022 $1,043,848 -$727,690 -230% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2023 2022 FY
2021 $316,158 06 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.